This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
Articles
August 1, 2022
Dedicated volunteer Michelle Ratty was recognized at an awards luncheon at Gillette Stadium with the prestigious Myra Kraft Community MVP Award in honor of her remarkable volunteer service at Lowell General Hospital.